Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › Phase 2b CTR20232069 (vs semaglutide)

Phase 2b CTR20232069 (vs semaglutide)

Bofanglutide (GZR18) · t2d

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Bofanglutide (GZR18)
Population
t2d
Phase
2
Participants
264
Duration
24 weeks

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
12 mg Q2W vs semaglutide 1 mg QW (active comparator): HbA1c -1.6t2d china24264——−1.9——————press release
18 mg Q2W vs semaglutide 1 mg QW (active comparator): HbA1c -1.6t2d china24264——−2.3——————press release
24 mg Q2W vs semaglutide 1 mg QW (active comparator): HbA1c -1.6t2d china24264——−1.9——————press release
24 mg QW vs semaglutide 1 mg QW (active comparator): HbA1c -1.6t2d china24264——−2.3——————press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (4)
  • 12 mg Q2W · hba1c · press release
    1.87% (12 mg, bi-weekly), 2.28% (18 mg, bi-weekly), 1.94% (24 mg, bi-weekly), and 2.32% (24 mg, once-weekly), all higher than the semaglutide group (1.60% reduction)
  • 18 mg Q2W · hba1c · press release
    1.87% (12 mg, bi-weekly), 2.28% (18 mg, bi-weekly), 1.94% (24 mg, bi-weekly), and 2.32% (24 mg, once-weekly), all higher than the semaglutide group (1.60% reduction)
  • 24 mg Q2W · hba1c · press release
    1.87% (12 mg, bi-weekly), 2.28% (18 mg, bi-weekly), 1.94% (24 mg, bi-weekly), and 2.32% (24 mg, once-weekly), all higher than the semaglutide group (1.60% reduction)
  • 24 mg QW · hba1c · press release
    1.87% (12 mg, bi-weekly), 2.28% (18 mg, bi-weekly), 1.94% (24 mg, bi-weekly), and 2.32% (24 mg, once-weekly), all higher than the semaglutide group (1.60% reduction)

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: Phase 2b CTR20232069 (vs semaglutide). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/phase-2b-ctr20232069/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.